Clinical research associates (CRAs) spend less than half of their time conducting ‘on site’ monitoring with training, travel and admin taking up the majority of their time according to new research
Quintiles has invested £3m ($4.6m) in a new UK-based biomarker R&D company in a continuation of its efforts to build in the field of personalised medicines.
VivoPharm says its new agreement with primary patient-derived tumour creators EPO-GmbH will bring drug candidate selection to a “new level” for US drug researchers.
Study payment tech firm Greenphire says partnership with Merge Healthcare’s trial arm will offer greater efficiencies for pharmaceutical industry sponsors.
inVentiv Health says it will now offer a one-stop-shop for pharma and biotech training services after merging its subsidiaries Pharmaceutical Institute and Preceptiv Learning Solutions.
Swiss API maker Carbogen Amcis has bought French contract manufacturer Creapharm Parenterals to boost capabilities in early-phase high potency drug development.
Outsourcing-Pharma presents a round-up of the latest contract manufacturing headlines in the industry, including news from Nanohale, Fleming and Trophogen.
Cyprotex says bigger preclinical CROs are stuck in toxicity testing ‘time warp’, citing drug industry demand for innovative cellular methods as key to its second half performance.
Custom antibody manufacturer Cambridge Research Biochemicals (CRB) has expanded its range of labelling dyes through a new agreement with supplier Life Technologies.
Ashland says it will ramp up production of the tablet disintegrant and dissolution aid polyvinylpyrrolidone (PVPP) to meet growing drug industry demand.
Amarin plans to add a fourth API maker to its supply chain as it prepares for a potential launch of its triglyceride lowering therapy, AMR101, in the US in 2012.
Sigma-Aldrich says it is a step closer to becoming a one-stop-shop for biopharmas in the drug discovery process after it inked a takeover agreement with biological testing firm BioReliance.
Drug delivery tech firm SkyePharma has started reviewing operations at its facility in Muttenz, Switzerland in a move that could results in significant job cuts.
A prior relationship rather than price was the most significant factor in helping Icon win its strategic deal with Shire according to an analyst who says such a trend is good for the sector.
Chinese companies exporting drugs in bulk will come under the microscope next month when the Indian government sends a team of officials to inspect manufacturing plants.
